Liver cancer drugs under Real-World watch in korea
NCT ID NCT06544629
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study monitors the safety and effectiveness of two drugs, Imjudo and Imfinzi, for people with liver cancer (hepatocellular carcinoma) in Korea. About 246 patients who are already eligible for these drugs under Korean guidelines will be observed in real-world settings. The goal is to track side effects and how well the drugs control the cancer, but this is not a cure study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGBusan, South Korea
-
Research Site
RECRUITINGGoyang, South Korea
-
Research Site
RECRUITINGSeongnam, South Korea
-
Research Site
RECRUITINGSeoul, South Korea
-
Research Site
NOT_YET_RECRUITINGSeoul, South Korea
-
Research Site
RECRUITINGSuwon, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?